Company profile for Piramal Pharma Solutions

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
18655 Krause St, Riverview, MI 48193
Telephone
Telephone
+1 734 282 3370
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
“Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”
This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

Impressions: 5049

https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

Radio Compass
16 Dec 2024

VLOG #PharmaReel

[Sponsored by another company]

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) approved fewer drugs, there was a significant increase in medical breakthroughs.While the CDER approved 50 new drugs in 2024, as compared to 55 in 2023, the CBER granted 14 biologics approvals in 2024, down from 20 in 2023.The European Medicines Agency (EMA) approved 34 new therapies, up from 32 in 2023, while Health Canada granted 28 approvals, down from 38 in 2023.The year saw long-awaited treatments being approved in areas such as schizophrenia and Alzheimer’s disease in the second half (H2) of 2024. In H1 2024, drugs to treat metabolic dysfunction-associated steatohepatitis (MASH) and chronic obstructive pulmonary disease (COPD) had been granted FDA approvals.As the year drew to a close, FDA began approving drugs at a feverish pace, with 29 of the CDER’s 50 approvals coming in H2.Like most years, the landscape of drug approvals was dominated by oncology, with 15 of the 50 drugs (30 percent) approved targeting various forms of cancer. This was followed by dermatology and non-malignant hematology, each accounting for 12 percent of approvals. Notably, small molecules continued to dominate the market, making up for 64 percent of the new drug approvals, while 32 percent were proteins, including monoclonal and bi-specific antibodies. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available)Karuna-BMS’ schizophrenia drug, Lilly’s Alzheimer’s med, Neurocrine’s Crenessity dominate list of pathbreaking approvals in H2Out of the 50 new drugs approved in 2024, CDER identified 24 (48 percent) as first-in-class, showcasing novel mechanisms of action. The most anticipated approval of 2024 was Karuna and Bristol Myers Squibb’s Cobenfy, a groundbreaking treatment for schizophrenia. This fixed-dose combination of xanomeline and trospium chloride represents the first novel mechanism of action in decades for this debilitating psychiatric condition. Analysts forecast peak annual sales of over US$ 3.3 billion for Cobenfy. Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) became the third amyloid-targeting antibody to gain FDA approval. Unlike its predecessors, Kisunla offers a unique limited-duration treatment regimen, allowing patients to discontinue therapy once amyloid levels in the brain drop below a certain threshold. Priced at approximately US$ 32,000 per year, it is positioned as a cost-effective alternative to existing treatments. Analysts estimate peak sales of US$ 2.4 billion for Kisunla.Crenessity (crinecerfont), developed by Neurocrine Biosciences, became the first FDA-approved treatment in decades for classic congenital adrenal hyperplasia (genetic conditions that affect the adrenal glands). Similarly, Vertex’s triple combination therapy of deutivacaftor, tezacaftor & vanzacaftor (Alyftrek) for cystic fibrosis represents a significant advancement in genetic disease treatment. Analysts forecast peak sales exceeding US$ 8.3 billion, underscoring the therapy’s potential to transform patient care.Meanwhile, Bridgebio’s Attruby (acoramidis hydrochloride) emerged as a promising treatment for cardiac amyloidosis, a life-threatening condition. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Roche’s Itovebi, Checkpoint’s Unloxcyt clinch FDA approvals in H2 2024; forecast to achieve blockbuster statusThe dominance of cancer drug approvals reflects the ongoing focus on targeted therapies, immuno-oncology, and precision medicine to improve outcomes for patients with hard-to-treat cancers.Among the year’s notable FDA approvals was Genentech’s Itovebi (inavolisib), another targeted therapy that treats hormone receptor-positive (HR+), HER2-negative breast cancer. Itovebi is a PI3Kα inhibitor designed specifically for patients with PIK3CA mutations, a common driver of resistance to endocrine therapy in breast cancer. It demonstrated a more tolerable safety profile. Roche projects Itovebi’s peak (annual) sales to reach CHF 2 billion (US$ 2.3 billion).Checkpoint Therapeutics’ Unloxcyt (cosibelimab) joined the crowded checkpoint inhibitor market as the eleventh PD-1/PD-L1-targeting monoclonal antibody approved by the FDA. It was granted approval for cutaneous squamous cell carcinoma (cSCC), an aggressive form of skin cancer with high recurrence rates. As compared to other checkpoint inhibitors, like Keytruda (pembrolizumab) and Opdivo (nivolumab), Unloxcyt is likely to offer an advantage in immune activation.FDA also approved Astellas’ Vyloy (zolbetuximab), a first-in-class monoclonal antibody for metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Analysts forecast peak sales of approximately US$ 850 million for Vyloy.Syndax Pharmaceuticals’ Revuforj (revumenib) was approved by FDA to treat a type of acute leukemia in both adults and children. This approval introduces a novel class of medications known as menin inhibitors. These agents are currently in clinical development for the treatment of genetically defined subsets of acute leukemia. These inhibitors function by preventing the activation of cancer growth-related proteins. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Potential blockbusters Lilly’s Ebglyss, Galderma’s Nemluvio lead advances in dermatologyEli Lilly’s Ebglyss (lebrikizumab) garnered significant attention. Approved by FDA for moderate-to-severe atopic dermatitis, this monoclonal antibody introduces a less burdensome dosing regimen compared to its competitors, with maintenance therapy required only once a month. This feature positions it as a potential contender to Dupixent (dupilumab), a market leader in atopic dermatitis. Ebglyss sales are forecast to reach US$ 1.9 billion by 2030.Galderma’s Nemluvio (nemolizumab) secured FDA approval for two indications in 2024 — prurigo nodularis (a chronic disorder of the skin) and moderate-to-severe atopic dermatitis in patients aged 12 years and older. As the first humanized IgG2 monoclonal antibody targeting the IL-31 receptor, Nemluvio directly inhibits the key driver of itch and inflammation in both these conditions. With its unique mechanism and broad dermatology potential, analysts forecast peak sales of approximately US$ 1.66 billion. Ebglyss and Nemluvio underscore the growing importance of biologics in dermatological care.Botanix Pharmaceuticals also made strides in dermatology by clinching an FDA approval for Sofdra (sofpironium) in June. The drug has been okayed for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive sweating.Ascendis Pharma’s Yorvipath (palopegteriparatide), a therapy approved by FDA to treat hypoparathyroidism, is forecast to achieve blockbuster sales of US$ 1.8 billion by 2030, highlighting its potential to transform endocrine care. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Our viewOverall, 2024 was defined by its breakthrough drug approvals. The year also saw significant reduction in complete response letters (CRLs) — they dropped from 43 in 2023 to just 29 in 2024. This suggests improved industry preparedness and alignment with regulatory expectations.The new year began with the approval of Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo, marking a significant advancement in oncology. Several other promising new drugs are coming up for FDA approval this year, such as J&J’s nipocalimab, Vertex Pharmaceuticals’ suzetrigine, Elevar Therapeutics’ rivoceranib/camrelizumab, Sanofi’s fitusiran and GSK’s gepotidacin. Hopefully, the momentum of breakthrough approvals will continue through 2025, political headwinds in the US notwithstanding. 

Impressions: 619

https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies

#PharmaFlow by PHARMACOMPASS
30 Jan 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.business-standard.com/markets/news/piramal-pharma-surges-4-after-launching-drug-for-psychiatric-disorders-125012300441_1.html

BUSINESS STD
23 Jan 2025

https://www.business-standard.com/markets/capital-market-news/piramal-pharma-launches-chlorpromazine-hydrochloride-in-us-125012300245_1.html

BUSINESS STD
23 Jan 2025

https://www.business-standard.com/markets/capital-market-news/volumes-spurt-at-piramal-pharma-ltd-counter-125011300546_1.html

BUSINESS STD
13 Jan 2025

https://www.business-standard.com/markets/capital-market-news/piramal-pharma-gains-on-appointing-sai-ramana-ponugoti-as-ceo-of-ich-125010700386_1.html

BUSINESS STD
07 Jan 2025

https://www.business-standard.com/markets/news/piramal-pharma-up-7-as-jm-financial-initiates-with-buy-36-upside-eyed-124121700218_1.html

BUSINESS STD
17 Dec 2024

https://www.business-standard.com/companies/news/piramal-pharma-to-pay-407-400-to-us-based-vetdc-inc-to-settle-dispute-124120601004_1.html

BUSINESS STD
07 Dec 2024

LISTED APIs

read-more
read-more
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

01

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

02

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

03

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

04

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

05

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

06

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

07

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

08

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

09

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, ...
Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.
blank

10

VMX
Not Confirmed
arrow
arrow
VMX
Not Confirmed

Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia through a globally integrated network of facilities. It offers a range of services from drug discovery to commercial supply of APIs and finished dosage forms, along with specialized services like HPAPIs, antibody drug conjugations, sterile fill/finish, peptide products and services and potent solid oral drug products. PPS also provides services for biologics, including vaccines, gene therapies and monoclonal antibodies through its subsidiary Yapan Bio.

About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europe and Asia thr...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Services

Upload your portfolio for free, ask us

Packaging

Click here to discover the service providers for Packaging

Analytical

Click here to discover the service providers for Analytical

API Manufacturing

Click here to discover the service providers for API Manufacturing

Drug Product Manufacturing

Click here to discover the service providers for Drug Product Manufacturing

API & Drug Product Development

Click here to discover the service providers for API & Drug Product Development

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Piramal Pharma Solutions and get a quotation

Piramal Pharma Solutions is a supplier offers 102 products (APIs, Excipients or Intermediates).

Find a price of Diltiazem Hydrochloride bulk with DMF, CEP, JDMF, WC offered by Piramal Pharma Solutions

Find a price of Ketoconazole bulk with DMF, CEP, JDMF, WC offered by Piramal Pharma Solutions

Find a price of Amiodarone Hydrochloride bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Aprepitant bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Baclofen bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Bisoprolol Fumarate bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Entacapone bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Fosaprepitant bulk with DMF, JDMF, WC offered by Piramal Pharma Solutions

Find a price of Perindopril Erbumine bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Pramipexole Dihydrochloride bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Trazodone Hydrochloride bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Verapamil Hydrochloride bulk with DMF, CEP, WC offered by Piramal Pharma Solutions

Find a price of Desmopressin Acetate bulk with DMF, CEP offered by Piramal Pharma Solutions

Find a price of Leuprolide Acetate bulk with DMF, CEP offered by Piramal Pharma Solutions

Find a price of Oxytocin bulk with DMF, CEP offered by Piramal Pharma Solutions

Find a price of Aciclovir bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Armodafinil bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Brimonidine Tartrate bulk with CEP, WC offered by Piramal Pharma Solutions

Find a price of Cinacalcet Hydrochloride bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Clobazam bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Dabigatran Etexilate Mesylate bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Deferasirox bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Donepezil bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Flecainide bulk with CEP, WC offered by Piramal Pharma Solutions

Find a price of Levobunolol bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Lurasidone Hydrochloride bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Mebeverine bulk with CEP, WC offered by Piramal Pharma Solutions

Find a price of Misoprostol bulk with DMF, CEP offered by Piramal Pharma Solutions

Find a price of Oxybutynin Hydrochloride bulk with CEP, WC offered by Piramal Pharma Solutions

Find a price of Paliperidone Palmitate bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Rivaroxaban bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Sulindac bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Tetrabenazine bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Tramadol Hydrochloride bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Valacyclovir Hydrochloride bulk with DMF, WC offered by Piramal Pharma Solutions

Find a price of Buserelin Acetate bulk with CEP offered by Piramal Pharma Solutions

Find a price of Calcitonin bulk with CEP offered by Piramal Pharma Solutions

Find a price of Cetrorelix Acetate bulk with DMF offered by Piramal Pharma Solutions

Find a price of Somatostatin bulk with CEP offered by Piramal Pharma Solutions

Find a price of Terlipressin Acetate bulk with CEP offered by Piramal Pharma Solutions

Find a price of Abacavir Sulfate bulk with WC offered by Piramal Pharma Solutions

Find a price of Anagrelide Hydrochloride bulk with DMF offered by Piramal Pharma Solutions

Find a price of Arginine Vasopressin bulk with DMF offered by Piramal Pharma Solutions

Find a price of Azilsartan bulk with DMF offered by Piramal Pharma Solutions

Find a price of Bexagliflozin bulk with WC offered by Piramal Pharma Solutions

Find a price of Cloprostenol Sodium bulk with DMF offered by Piramal Pharma Solutions

Find a price of Dapagliflozin Propanediol Monohydrate bulk with DMF offered by Piramal Pharma Solutions

Find a price of Dexlansoprazole bulk with DMF offered by Piramal Pharma Solutions

Find a price of Diltiazem Hydrochloride bulk with CEP offered by Piramal Pharma Solutions

Find a price of Dronedarone Hydrochloride bulk with DMF offered by Piramal Pharma Solutions

Find a price of Droxidopa bulk with DMF offered by Piramal Pharma Solutions

Find a price of Empagliflozin bulk with DMF offered by Piramal Pharma Solutions

Find a price of Gemfibrozil bulk with DMF offered by Piramal Pharma Solutions

Find a price of Halothane bulk with WC offered by Piramal Pharma Solutions

Find a price of Ibuprofen bulk with CEP offered by Piramal Pharma Solutions

Find a price of Irbesartan bulk with DMF offered by Piramal Pharma Solutions

Find a price of Isoflurane bulk with WC offered by Piramal Pharma Solutions

Find a price of Levoketoconazole bulk with DMF offered by Piramal Pharma Solutions

Find a price of Metaxalone bulk with DMF offered by Piramal Pharma Solutions

Find a price of Mirabegron bulk with DMF offered by Piramal Pharma Solutions

Find a price of Octreotide Acetate bulk with DMF offered by Piramal Pharma Solutions

Find a price of Octreotide Acetate bulk offered by Piramal Pharma Solutions

Find a price of Oxytocin bulk with DMF offered by Piramal Pharma Solutions

Find a price of Pregabalin bulk with DMF offered by Piramal Pharma Solutions

Find a price of Quetiapine Hemifumarate bulk with DMF offered by Piramal Pharma Solutions

Find a price of Tafenoquine Succinate bulk with WC offered by Piramal Pharma Solutions

Find a price of Tolcapone bulk with WC offered by Piramal Pharma Solutions

Find a price of Varenicline Tartrate bulk with DMF offered by Piramal Pharma Solutions

Find a price of Verapamil Hydrochloride bulk with CEP offered by Piramal Pharma Solutions

Find a price of Vortioxetine Hydrobromide bulk with DMF offered by Piramal Pharma Solutions

Find a price of Bexagliflozin bulk offered by Piramal Pharma Solutions

Find a price of Carbetocin Acetate bulk offered by Piramal Pharma Solutions

Find a price of Gonadorelin Acetate bulk offered by Piramal Pharma Solutions

Find a price of Spironolactone bulk offered by Piramal Pharma Solutions

Find a price of Tetracosactide bulk offered by Piramal Pharma Solutions

Find a price of Abaloparatide Acetate bulk offered by Piramal Pharma Solutions

Find a price of Apixaban bulk offered by Piramal Pharma Solutions

Find a price of Apremilast bulk offered by Piramal Pharma Solutions

Find a price of Atosiban bulk offered by Piramal Pharma Solutions

Find a price of Camylofin Dihydrochloride bulk offered by Piramal Pharma Solutions

Find a price of Canagliflozin bulk offered by Piramal Pharma Solutions

Find a price of Corticotropin bulk offered by Piramal Pharma Solutions

Find a price of Degarelix Acetate bulk offered by Piramal Pharma Solutions

Find a price of Desvenlafaxine Succinate bulk offered by Piramal Pharma Solutions

Find a price of Edoxaban Tosylate bulk offered by Piramal Pharma Solutions

Find a price of Glatiramer Acetate bulk offered by Piramal Pharma Solutions

Find a price of Glucagon bulk offered by Piramal Pharma Solutions

Find a price of Goserelin Acetate bulk offered by Piramal Pharma Solutions

Find a price of Lanreotide Acetate bulk offered by Piramal Pharma Solutions

Find a price of Lercanidipine bulk offered by Piramal Pharma Solutions

Find a price of Linaclotide bulk offered by Piramal Pharma Solutions

Find a price of Linagliptin bulk offered by Piramal Pharma Solutions

Find a price of Liraglutide bulk offered by Piramal Pharma Solutions

Find a price of Paliperidone bulk offered by Piramal Pharma Solutions

Find a price of Plecanatide bulk offered by Piramal Pharma Solutions

Find a price of Semaglutide bulk offered by Piramal Pharma Solutions

Find a price of Sugammadex Sodium bulk offered by Piramal Pharma Solutions

Find a price of Sulfiram bulk offered by Piramal Pharma Solutions

Find a price of Teduglutide bulk offered by Piramal Pharma Solutions

Find a price of Trientine Hydrochloride bulk offered by Piramal Pharma Solutions

Find a price of Triptorelin Acetate bulk offered by Piramal Pharma Solutions

Find a price of Valacyclovir bulk offered by Piramal Pharma Solutions

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty